{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T04:37:16Z","timestamp":1792816636570,"version":"4.5.0"},"reference-count":77,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001843","name":"Anusandhan National Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001843","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.bbrc.2026.154613","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T03:39:19Z","timestamp":1790134759000},"page":"154613","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Identification of repositioned inhibitors of pan-cancer proteasomal target as potential anti-proliferative candidates using a computational therapeutics approach"],"prefix":"10.1016","volume":"838","author":[{"given":"Parminder","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0090-2779","authenticated-orcid":false,"given":"Ashok","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1682-638X","authenticated-orcid":false,"given":"Nilambra","family":"Dogra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2026.154613_bib1","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2174\/156800911794519752","article-title":"Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives","volume":"11","author":"Chen","year":"2011","journal-title":"Curr. Cancer Drug Targets"},{"issue":"7","key":"10.1016\/j.bbrc.2026.154613_bib2","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nrclinonc.2016.206","article-title":"Proteasome inhibitors in cancer therapy","volume":"14","author":"Manasanch","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bbrc.2026.154613_bib3","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.3390\/ijms22073440","article-title":"The molecular basis of ubiquitin-conjugating enzymes (E2s) as a potential target for cancer therapy","volume":"22","author":"Du","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.bbrc.2026.154613_bib4","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3892\/or.2023.8500","article-title":"Ubiquitin-conjugating enzymes as potential biomarkers and therapeutic targets for digestive system cancers","volume":"49","author":"Lei","year":"2023","journal-title":"Oncol. Rep."},{"issue":"1","key":"10.1016\/j.bbrc.2026.154613_bib5","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-72714-3","article-title":"The activation of the Notch signaling pathway by UBE2C promotes the proliferation and metastasis of hepatocellular carcinoma","volume":"14","author":"Zhan","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbrc.2026.154613_bib6","article-title":"UBE2C: a pan\u2010cancer diagnostic and prognostic biomarker revealed through bioinformatics analysis","volume":"7","author":"Jalali","year":"2024","journal-title":"Cancer Rep."},{"key":"10.1016\/j.bbrc.2026.154613_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2023.1170940","article-title":"UBE2C expression is elevated in hepatoblastoma and correlates with inferior patient survival","volume":"14","author":"Nousiainen","year":"2023","journal-title":"Front. Genet."},{"key":"10.1016\/j.bbrc.2026.154613_bib8","doi-asserted-by":"crossref","first-page":"674","DOI":"10.3390\/diagnostics10090674","article-title":"UBE2C is a potential biomarker for tumorigenesis and prognosis in tongue squamous cell carcinoma","volume":"10","author":"Liu","year":"2020","journal-title":"Diagnostics"},{"key":"10.1016\/j.bbrc.2026.154613_bib9","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/8607859","article-title":"UBE2C induces cisplatin resistance via ZEB1\/2-Dependent upregulation of ABCG2 and ERCC1 in NSCLC cells","volume":"2019","author":"Wu","year":"2019","journal-title":"J. Oncol."},{"key":"10.1016\/j.bbrc.2026.154613_bib10","first-page":"459","article-title":"Inhibition of ubiquitin conjugating enzyme UBE2C reduces proliferation and sensitizes breast cancer cells to radiation, doxorubicin, tamoxifen and letrozole","volume":"36","author":"Rawat","year":"2013","journal-title":"Cell. Oncol. (Dordrecht, Netherlands)"},{"key":"10.1016\/j.bbrc.2026.154613_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.218013","article-title":"UBE2C promotes pancreatic tumorigenesis by KRAS stabilization via APC\/CCDH1-mediated WDR76 degradation","volume":"633","author":"Wang","year":"2025","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bbrc.2026.154613_bib12","doi-asserted-by":"crossref","DOI":"10.1172\/JCI162434","article-title":"The UBE2C\/CDH1\/DEPTOR axis is an oncogene and tumor suppressor cascade in lung cancer cells","volume":"133","author":"Zhang","year":"2023","journal-title":"J. Clin. Investig."},{"issue":"7017","key":"10.1016\/j.bbrc.2026.154613_bib13","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/nature03023","article-title":"Autonomous regulation of the anaphase-promoting complex couples mitosis to S-phase entry","volume":"432","author":"Rape","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2026.154613_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2407-13-192","article-title":"High expression of ubiquitin-conjugating enzyme 2C (UBE2C) correlates with nasopharyngeal carcinoma progression","volume":"13","author":"Shen","year":"2013","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bbrc.2026.154613_bib15","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1593\/neo.05832","article-title":"Expression and effect of inhibition of the ubiquitin-conjugating enzyme E2C on esophageal adenocarcinoma","volume":"8","author":"Lin","year":"2006","journal-title":"Neoplasia"},{"key":"10.1016\/j.bbrc.2026.154613_bib16","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1016\/j.ajpath.2011.01.034","article-title":"Bortezomib stabilizes mitotic cyclins and prevents cell cycle progression via inhibition of UBE2C in colorectal carcinoma","volume":"178","author":"Bavi","year":"2011","journal-title":"Am. J. Pathol."},{"issue":"39","key":"10.1016\/j.bbrc.2026.154613_bib17","doi-asserted-by":"crossref","first-page":"6621","DOI":"10.1038\/sj.onc.1207861","article-title":"Overexpression, genomic amplification and therapeutic potential of inhibiting the UbcH10 ubiquitin conjugase in human carcinomas of diverse anatomic origin","volume":"23","author":"Wagner","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.bbrc.2026.154613_bib18","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/ijc.22605","article-title":"Identification of overexpressed genes in hepatocellular carcinoma, with special reference to ubiquitin-conjugating enzyme E2C gene expression","volume":"121","author":"Ieta","year":"2007","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bbrc.2026.154613_bib19","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1016\/j.ejca.2007.09.003","article-title":"UbcH10 is overexpressed in malignant breast carcinomas","volume":"43","author":"Berlingieri","year":"2007","journal-title":"Eur. J. Cancer"},{"issue":"14","key":"10.1016\/j.bbrc.2026.154613_bib20","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1038\/sj.onc.1210010","article-title":"UbcH10 expression may be a useful tool in the prognosis of ovarian carcinomas","volume":"26","author":"Berlingieri","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.bbrc.2026.154613_bib21","doi-asserted-by":"crossref","first-page":"219","DOI":"10.5414\/NPP27219","article-title":"Analysis of UbcH10 expression represents a useful tool for the diagnosis and therapy of astrocytic tumors","volume":"27","author":"Donato","year":"2008","journal-title":"Clin. Neuropathol."},{"key":"10.1016\/j.bbrc.2026.154613_bib22","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1111\/j.1365-2559.2009.03296.x","article-title":"UbcH10 expression in human lymphomas","volume":"54","author":"Troncone","year":"2009","journal-title":"Histopathology"},{"key":"10.1016\/j.bbrc.2026.154613_bib23","article-title":"Pan-cancer bioinformatics analysis of gene UBE2C","volume":"13","author":"Yuan","year":"2022","journal-title":"Front. Genet."},{"key":"10.1016\/j.bbrc.2026.154613_bib24","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.2147\/OTT.S485053","article-title":"Ubiquitination-binding enzyme 2C is associated with cancer development and prognosis and is a potential therapeutic target","volume":"17","author":"Zhao","year":"2024","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.bbrc.2026.154613_bib25","doi-asserted-by":"crossref","first-page":"4866","DOI":"10.1158\/0008-5472.CAN-10-4576","article-title":"CCI-779 inhibits cell-cycle G2-M progression and invasion of castration-resistant prostate cancer via attenuation of UBE2C transcription and mRNA stability","volume":"71","author":"Wang","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbrc.2026.154613_bib26","first-page":"1","article-title":"UBE2C promotes LUAD progression by ubiquitin-dependent degradation of p53 to inactivate the p53\/p21 signaling pathway","volume":"15","author":"Huang","year":"2024","journal-title":"Discov. Oncol."},{"key":"10.1016\/j.bbrc.2026.154613_bib27","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1080\/15384101.2017.1356507","article-title":"Forkhead Box M1 positively regulates UBE2C and protects glioma cells from autophagic death","volume":"16","author":"Guo","year":"2017","journal-title":"Cell Cycle"},{"key":"10.1016\/j.bbrc.2026.154613_bib28","doi-asserted-by":"crossref","first-page":"188","DOI":"10.3390\/genes9040188","article-title":"UBE2C is a transcriptional target of the cell cycle regulator FOXM1","volume":"9","author":"Nicolau-Neto","year":"2018","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.bbrc.2026.154613_bib29","doi-asserted-by":"crossref","first-page":"14231","DOI":"10.1074\/jbc.M116.731398","article-title":"E2 ubiquitin-conjugating enzyme, UBE2C gene, is reciprocally regulated by wild-type and gain-of-function mutant p53","volume":"291","author":"Bajaj","year":"2016","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbrc.2026.154613_bib30","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1126\/sciadv.adj3010","article-title":"Accelerating drug discovery and repurposing by combining transcriptional signature connectivity with docking","volume":"10","author":"Thorman","year":"2024","journal-title":"Sci. Adv."},{"key":"10.1016\/j.bbrc.2026.154613_bib31","doi-asserted-by":"crossref","first-page":"W98","DOI":"10.1093\/nar\/gkx247","article-title":"GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses","volume":"45","author":"Tang","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bbrc.2026.154613_bib32","doi-asserted-by":"crossref","first-page":"W509","DOI":"10.1093\/nar\/gkaa407","article-title":"TIMER2.0 for analysis of tumor-infiltrating immune cells","volume":"48","author":"Li","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bbrc.2026.154613_bib33","doi-asserted-by":"crossref","DOI":"10.1126\/science.aan2507","article-title":"A pathology atlas of the human cancer transcriptome","volume":"357","author":"Uhlen","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.bbrc.2026.154613_bib34","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1074\/mcp.M500279-MCP200","article-title":"A human protein atlas for normal and cancer tissues based on antibody proteomics","volume":"4","author":"Uhl\u00e9n","year":"2005","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.bbrc.2026.154613_bib35","doi-asserted-by":"crossref","first-page":"W214","DOI":"10.1093\/nar\/gkq537","article-title":"The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function","volume":"38","author":"Warde-Farley","year":"2010","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bbrc.2026.154613_bib36","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/s41586-019-1103-9","article-title":"Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens","volume":"568","author":"Behan","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2026.154613_bib37","first-page":"1","volume":"10","author":"Zhou","year":"2019"},{"key":"10.1016\/j.bbrc.2026.154613_bib38","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/978-1-4939-2269-7_19","article-title":"Small-molecule library screening by docking with PyRx","volume":"1263","author":"Dallakyan","year":"2015","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.bbrc.2026.154613_bib39","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1002\/jcc.21256","article-title":"AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility","volume":"30","author":"Morris","year":"2009","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.bbrc.2026.154613_bib40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2105-9-396","article-title":"FAF-Drugs2: free ADME\/tox filtering tool to assist drug discovery and chemical biology projects","volume":"9","author":"Lagorce","year":"2008","journal-title":"BMC Bioinf."},{"key":"10.1016\/j.bbrc.2026.154613_bib41","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1093\/bioinformatics\/btt055","article-title":"GROMACS 4.5: a high-throughput and highly parallel open source molecular simulation toolkit","volume":"29","author":"Pronk","year":"2013","journal-title":"Bioinformatics"},{"key":"10.1016\/j.bbrc.2026.154613_bib42","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1021\/ct300418h","article-title":"MMPBSA.py: an efficient program for end-state free energy calculations","volume":"8","author":"Miller","year":"2012","journal-title":"J. Chem. Theor. Comput."},{"key":"10.1016\/j.bbrc.2026.154613_bib43","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/nrc1951","article-title":"The NCI60 human tumour cell line anticancer drug screen","volume":"6","author":"Shoemaker","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbrc.2026.154613_bib44","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1093\/jnci\/81.14.1088","article-title":"Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm","volume":"81","author":"Paull","year":"1989","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.bbrc.2026.154613_bib45","doi-asserted-by":"crossref","first-page":"9250","DOI":"10.1021\/acsomega.2c07416","article-title":"National cancer institute (NCI) program for natural product discovery: exploring NCI-60 screening data of natural product samples with artificial neural networks","volume":"8","author":"Evans","year":"2023","journal-title":"ACS Omega"},{"key":"10.1016\/j.bbrc.2026.154613_bib46","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.cell.2017.06.010","article-title":"Defining a cancer dependency map","volume":"170","author":"Tsherniak","year":"2017","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.bbrc.2026.154613_bib47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-022-32205-3","article-title":"Connecting omics signatures and revealing biological mechanisms with iLINCS","volume":"13","author":"Pilarczyk","year":"2022","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.bbrc.2026.154613_bib48","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41416-020-01048-4","article-title":"Cytotoxic CD8+ T cells in cancer and cancer immunotherapy","volume":"124","author":"Raskov","year":"2020","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bbrc.2026.154613_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.101134","article-title":"The association between CD8+ tumor-infiltrating lymphocytes and the clinical outcome of cancer immunotherapy: a systematic review and meta-analysis","volume":"41","author":"Li","year":"2021","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.bbrc.2026.154613_bib50","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1200\/JCO.2010.30.5037","article-title":"Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer","volume":"29","author":"Mahmoud","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbrc.2026.154613_bib51","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.972021","article-title":"Roles of CD4+ T cells as mediators of antitumor immunity","volume":"13","author":"Kravtsov","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbrc.2026.154613_bib52","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.trecan.2024.07.009","article-title":"CD4+ T cells in antitumor immunity","volume":"10","author":"Montauti","year":"2024","journal-title":"Trends Cancer"},{"key":"10.1016\/j.bbrc.2026.154613_bib53","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1111\/cas.14069","article-title":"Regulatory T (Treg) cells in cancer: can Treg cells be a new therapeutic target?","volume":"110","author":"Ohue","year":"2019","journal-title":"Cancer Sci."},{"key":"10.1016\/j.bbrc.2026.154613_bib54","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/j.trecan.2022.06.008","article-title":"Therapeutic targeting of regulatory T cells in cancer","volume":"8","author":"Shan","year":"2022","journal-title":"Trends Cancer"},{"key":"10.1016\/j.bbrc.2026.154613_bib55","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ccell.2023.02.014","article-title":"Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy","volume":"41","author":"Tay","year":"2023","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.bbrc.2026.154613_bib56","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/s41571-019-0175-7","article-title":"Regulatory T cells in cancer immunosuppression \u2014 implications for anticancer therapy","volume":"16","author":"Togashi","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bbrc.2026.154613_bib57","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1007\/s12672-025-03385-3","article-title":"UBE2C-mediated ubiquitination of ACSL4 inhibits ferroptosis and promotes gastric cancer progression","volume":"16","author":"Yang","year":"2025","journal-title":"Discov. Oncol."},{"key":"10.1016\/j.bbrc.2026.154613_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.dnarep.2025.103901","article-title":"UBE2C promotes cell cycle progression and suppresses DNA damage-induced apoptosis in triple-negative breast cancer","volume":"154","author":"Hu","year":"2025","journal-title":"DNA Repair (Amst)"},{"key":"10.1016\/j.bbrc.2026.154613_bib59","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1139\/cjpp-2021-0577","article-title":"Anisomycin inhibits angiogenesis, growth, and survival of triple-negative breast cancer through mitochondrial dysfunction, AMPK activation, and mTOR inhibition","volume":"100","author":"Yang","year":"2022","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"10.1016\/j.bbrc.2026.154613_bib60","doi-asserted-by":"crossref","first-page":"8307","DOI":"10.1158\/0008-5472.CAN-07-1687","article-title":"A chemical screen identifies anisomycin as an anoikis sensitizer that functions by decreasing FLIP protein synthesis","volume":"67","author":"Mawji","year":"2007","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.bbrc.2026.154613_bib61","first-page":"1","article-title":"Novel natural killer cell-mediated cancer immunotherapeutic activity of anisomycin against hepatocellular carcinoma cells","volume":"8","author":"Kim","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbrc.2026.154613_bib62","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1080\/13880209.2024.2309891","article-title":"Cephaeline promotes ferroptosis by targeting NRF2 to exert anti-lung cancer efficacy","volume":"62","author":"Chen","year":"2024","journal-title":"Pharm. Biol."},{"key":"10.1016\/j.bbrc.2026.154613_bib63","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/jop.13252","article-title":"Cephaeline is an inductor of histone H3 acetylation and inhibitor of mucoepidermoid carcinoma cancer stem cells","volume":"51","author":"Silva","year":"2022","journal-title":"J. Oral Pathol. Med."},{"key":"10.1016\/j.bbrc.2026.154613_bib64","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00018-023-04910-9","article-title":"The mechanistic role of cardiac glycosides in DNA damage response and repair signaling","volume":"80","author":"Ainembabazi","year":"2023","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.bbrc.2026.154613_bib65","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s11418-024-01830-1","article-title":"Search for new steroidal glycosides with anti-cancer potential from natural resources","volume":"78","author":"Matsuo","year":"2024","journal-title":"J. Nat. Med."},{"key":"10.1016\/j.bbrc.2026.154613_bib66","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1517\/14728222.11.8.1043","article-title":"Digitoxin as an anticancer agent with selectivity for cancer cells: possible mechanisms involved","volume":"11","author":"L\u00f3pez-L\u00e1zaro","year":"2007","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.bbrc.2026.154613_bib67","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1054\/mehy.1999.0985","article-title":"Digitoxin is a potential anticancer agent for several types of cancer","volume":"53","author":"Haux","year":"1999","journal-title":"Med. Hypotheses"},{"key":"10.1016\/j.bbrc.2026.154613_bib68","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.biopha.2017.10.128","article-title":"Cytotoxic and cytostatic effects of digitoxigenin monodigitoxoside (DGX) in human lung cancer cells and its link to Na,K-ATPase","volume":"97","author":"Schneider","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bbrc.2026.154613_bib69","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1021\/np050226l","article-title":"Digitoxin inhibits the growth of cancer cell lines at concentrations commonly found in cardiac patients","volume":"68","author":"L\u00f3pez-L\u00e1zaro","year":"2005","journal-title":"J. Nat. Prod."},{"key":"10.1016\/j.bbrc.2026.154613_bib70","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1158\/1535-7163.MCT-11-0421","article-title":"Digitoxin-induced cytotoxicity in cancer cells is mediated through distinct kinase and interferon signaling networks","volume":"10","author":"Prassas","year":"2011","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.bbrc.2026.154613_bib71","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1124\/mol.104.007302","article-title":"Digitalis-induced signaling by Na+\/K+-ATPase in human breast cancer cells","volume":"67","author":"Kometiani","year":"2005","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bbrc.2026.154613_bib72","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20211056","article-title":"Digoxin exerts anticancer activity on human nonsmall cell lung cancer cells by blocking PI3K\/Akt pathway","volume":"41","author":"Wang","year":"2021","journal-title":"Biosci. Rep."},{"key":"10.1016\/j.bbrc.2026.154613_bib73","doi-asserted-by":"crossref","first-page":"19579","DOI":"10.1073\/pnas.0809763105","article-title":"Digoxin and other cardiac glycosides inhibit HIF-1alpha synthesis and block tumor growth","volume":"105","author":"Zhang","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbrc.2026.154613_bib74","doi-asserted-by":"crossref","first-page":"995","DOI":"10.7150\/ijbs.44907","article-title":"Homoharringtonine inhibited breast cancer cells growth via miR-18a-3p\/AKT\/mTOR signaling pathway","volume":"17","author":"Bin Wang","year":"2021","journal-title":"Int. J. Biol. Sci."},{"issue":"8","key":"10.1016\/j.bbrc.2026.154613_bib75","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41419-020-02902-2","article-title":"Homoharringtonine suppresses tumor proliferation and migration by regulating EphB4-mediated \u03b2-catenin loss in hepatocellular carcinoma","volume":"11","author":"Zhu","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bbrc.2026.154613_bib76","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14194847","article-title":"Midostaurin modulates tumor microenvironment and enhances efficacy of Anti-PD-1 against Colon cancer","volume":"14","author":"Lai","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bbrc.2026.154613_bib77","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3390\/ph16020160","article-title":"Withaferin A: a pleiotropic anticancer agent from the Indian medicinal plant Withania somnifera (L.) dunal","volume":"16","author":"Kumar","year":"2023","journal-title":"Pharmaceuticals"}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X26013793?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X26013793?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:48:14Z","timestamp":1792813694000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X26013793"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":77,"alternative-id":["S0006291X26013793"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2026.154613","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identification of repositioned inhibitors of pan-cancer proteasomal target as potential anti-proliferative candidates using a computational therapeutics approach","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2026.154613","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"154613"}}